ArticleClinical kidney journal2025
Renal denervation in dialysis patients: long-term outcomes in a real-world setting.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology.Journal of nephrology · 2025Guideline
- Autonomic control of the vasculature in CKD: leveraging renal denervation.Frontiers in neuroscience · 2026Review
- Recent update on renal denervation: where do we stand now?Clinical hypertension · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Resistant hypertension is common in patients with end-stage kidney disease (ESKD) who are on dialysis. Experience with percutaneous renal denervation (RDN) in these patients is limited and generally has short follow-up periods, primarily focusing on blood pressure (BP) control. In particular, the effects of RDN on anaemia, chronic kidney disease-mineral and bone disorder (CKD-MBD) and dialysis tolerance remain unexamined. Methods: We report our experience with RDN in 14 dialysis patients [7 on haemodialysis (HD) and 7 on peritoneal dialysis (PD)] with a follow-up after RDN of 3-84 months. Six patients received kidney transplantation during follow-up. Results: BP and the number of antihypertensive drugs decreased ( Conclusion: Our experience with RDN in dialysis patients suggests beneficial effects in both HD and PD. BP improved significantly, with no observed issues related to the typical clinical problems faced by these patients, such as anaemia, CKD-MBD and dialysis tolerance. Furthermore, in those patients who received a kidney transplant, we noted a further improvement in BP control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.